Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample (N = 1119)

Schizophrenia Research

Volumn 170, Issue 1, 2016, Pages 217-221

  Helle, Siri ^a   Ringen, Petter Andreas ^b,c   Melle, Ingrid ^b,c   Larsen, Tor Ketil ^d,e   Gjestad, Rolf ^a   Johnsen, Erik ^a,e   Lagerberg, Trine Vik ^b,c   Andreassen, Ole A ^b,c   Kroken, Rune Andreas ^a,e   Joa, Inge ^d,f   ten Velden Hegelstad, Wenche ^d   Løberg, Else Marie ^a,e  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d STAVANGER UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF BERGEN   (Norway)

^f UNIVERSITY OF STAVANGER   (Norway)

Author keywords

Age at onset; Cannabis; Non affective psychosis; Schizophrenia; Substance; Substance use

Indexed keywords

CANNABIS; CENTRAL STIMULANT AGENT; COCAINE; OPIATE; PSYCHEDELIC AGENT;

ADULT; ARTICLE; CANNABIS USE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE ASSOCIATION; FAMILY HISTORY; FEMALE; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; ONSET AGE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRIORITY JOURNAL; PSYCHOSIS; SCHIZOPHRENIA SPECTRUM DISORDER; SEX DIFFERENCE; SUBSTANCE USE; CLINICAL TRIAL; COMPLICATION; FAMILY; MARIJUANA ABUSE; MULTICENTER STUDY; NORWAY; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; SCHIZOPHRENIA; YOUNG ADULT;

ADULT; AGE OF ONSET; CANNABIS; FAMILY; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; NORWAY; PSYCHOTIC DISORDERS; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEX FACTORS; YOUNG ADULT;

EID: 84960938315     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2015.11.027     Document Type: Article

References (37)

1. Abel K.M., Drake R., Goldstein J.M. Sex differences in schizophrenia. Int. Rev. Psychiatry 2010, 22(5):417-428.
2. Allegri F., Belvederi Murri M., Paparelli A., Marcacci T., Braca M., Menchetti M., Michetti R., Berardi D., Tarricone I. Current cannabis use and age of psychosis onset: a gender-mediated relationship? Results from an 8-year FEP incidence study in Bologna. Psychiatry Res. 2013, 210(1):368-370.
3. Barnes T.R., Mutsatsa S.H., Hutton S.B., Watt H.C., Joyce E.M. Comorbid substance use and age at onset of schizophrenia. Br. J. Psychiatry 2006, 188:237-242.
4. Barnett J.H., Werners U., Secher S.M., Hill K.E., Brazil R., Masson K., Pernet D.E., Kirkbride J.B., Murray G.K., Bullmore E.T., Jones P.B. Substance use in a population-based clinic sample of people with first-episode psychosis. Br. J. Psychiatry 2007, 190(6):515-520.
5. Bhavsar V. Environmental factors, including cannabis, are strongly related to the age of onset and morbidity of schizophrenia. Evid. Based Ment. Health 2015, 18(3):84.
6. Boydell J., Dean K., Dutta R., Giouroukou E., Fearon P., Murray R. A comparison of symptoms and family history in schizophrenia with and without prior cannabis use: implications for the concept of cannabis psychosis. Schizophr. Res. 2007, 93(1-3):203-210.
7. Breitborde N.J., Srihari V.H., Woods S.W. Review of the operational definition for first-episode psychosis. Early Interv. Psychiatry 2009, 3(4):259-265.
8. Curran P.J., West S.G., Finch J.F. The robustness of test statistics to nonnormality and specification error in confirmatory factor analysis. Psychol. Methods 1996, 1(1):16-29.
9. Di Forti M., Sallis H., Allegri F., Trotta A., Ferraro L., Stilo S.A., Marconi A., La Cascia C., Reis Marques T., Pariante C., Dazzan P., Mondelli V., Paparelli A., Kolliakou A., Prata D., Gaugrhan F., David A.S., Morgan C., Sthal D., Khondoker M., Maccabe J.H., Murray R.M. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr. Bull. 2013, 40(6):1509-1517.
10. Donoghue K., Doody G.A., Murray R.M., Jones P.B., Morgan C., Dazzan P., Hart J., Mazzoncini R., Maccabe J.H. Cannabis use, gender and age of onset of schizophrenia: data from the AESOP study. Psychiatry Res. 2014, 215(3):528-532.
11. Drake R.E., Mueser K.T., McHugo G.J. Clinical rating scales: Alcohol Use Scale (AUS), Drug Use Scale (DUS), and Substance Abuse Treatment Scale (SATS). Outcomes Assessment in Clinical Practice 1996, 113-116. Williams & Wilkins, Baltimore. L.I. Sederer, E. Dickey (Eds.).
12. Drake R.E., Osher F.C., Noordsy D.L., Hurlbut S.C., Teague G.B., Beaudett M.S. Diagnosis of alcohol use disorders in schizophrenia. Schizophr. Bull. 1990, 16(1):57-67.
13. First M.B., Spitzer R.L., Gibbon M., Williams G.M. Structured Clinical Interview of DSM-IV Axis I Disorders (SCID-I): Patient Edition. Version 2 1995, State Psychiatric Institute, Biometrics Research, NY, New York.
14. Friis S., Larsen T.K., Melle I., Opjordsmoen S., Johannessen J.O., Haahr U., Simonsen E., Rund B.R., Vaglum P., McGlashan T. Methodological pitfalls in early detection studies - the NAPE Lecture 2002. Nordic Association for Psychiatric Epidemiology. Acta Psychiatr. Scand. 2003, 107(1):3-9.
15. Goldberger C., Dervaux A., Gourion D., Bourdel M.C., Loo H., Laqueille X., Krebs M.O. Variable individual sensitivity to cannabis in patients with schizophrenia. Int. J. Neuropsychopharmacol. 2010, 13(9):1145-1154.
16. Hartz S.M., Pato C.N., Medeiros H., Cavazos-Rehg P., Sobell J.L., Knowles J.A., Bierut L.J., Pato M.T., for the Genomic Psychiatry Cohort, Consortium, Abbott C., Azevedo M.H., Belliveau R., Bevilacqua E., Bromet E.J., Buckley P.F., Dewan M.J., Escamilla M.A., Fanous A.H., Fochtmann L.J., Kinkead R., Kotov R., Lehrer D.S., Macciardi F., Malaspina D., Marder S.R., McCarroll S.A., Moran J., Morley C.P., Nicolini H., Perkins D.O., Potkin S.G., Purcell S.M., Rakofsky J.J., Rapaport M.H., Scolnick E.M., Sklar B., Sklar P., Smoller J.W., Sullivan P.F., Vivar A. Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiatry 2014, 71(3):248-254.
17. Joa I., Johannessen J.O., Auestad B., Friis S., McGlashan T., Melle I., Opjordsmoen S., Simonsen E., Vaglum P., Larsen T.K. The key to reducing duration of untreated first psychosis: information campaigns. Schizophr. Bull. 2008, 34(3):466-472.
18. Kay S.R., Opler L.A., Lindenmayer J.P. The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br. J. Psychiatry Suppl. 1989, 7:59-67.
19. Lagerberg T.V., Sundet K., Aminoff S.R., Berg A.O., Ringen P.A., Andreassen O.A., Melle I. Excessive cannabis use is associated with earlier age at onset in bipolar disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2011, 261(6):397-405.
20. Large M., Sharma S., Compton M.T., Slade T., Nielssen O. Cannabis use and earlier onset of psychosis: a systematic meta-analysis. Arch. Gen. Psychiatry 2011, 68(6):555-561. http://www.ncbi.nlm.nih.gov/pubmed/21300939.
21. Løberg E.M., Hugdahl K. Cannabis use and cognition in schizophrenia. Front. Hum. Neurosci. 2009, 3:53.
22. Mane A., Fernandez-Exposito M., Berge D., Gomez-Perez L., Sabate A., Toll A., Diaz L., Diez-Aja C., Perez V. Relationship between cannabis and psychosis: reasons for use and associated clinical variables. Psychiatry Res. 2015, 229(1-2):70-74.
23. McGuire P.K., Jones P., Harvey I., Williams M., McGuffin P., Murray R.M. Morbid risk of schizophrenia for relatives of patients with cannabis-associated psychosis. Schizophr. Res. 1995, 15(3):277-281.
24. McInnis M.G., McMahon F.J., Crow T., Ross C.A., DeLisi L.E. Anticipation in schizophrenia: a review and reconsideration. Am. J. Med. Genet. 1999, 88(6):686-693.
25. Myles H., Myles N., Large M. Cannabis use in first episode psychosis: meta-analysis of prevalence, and the time course of initiation and continued use. Aust. N. Z. J. Psychiatry. 2015, 10.1177/0004867415599846.
26. Myles N., Newall H., Nielssen O., Large M. The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr. Pharm. Des. 2012, 18(32):5055-5069.
27. Pedersen G., Hagtvet K.A., Karterud S. Generalizability studies of the Global Assessment of Functioning-split version. Compr. Psychiatry 2007, 48(1):88-94.
28. Power B.D., Dragovic M., Jablensky A., Stefanis N.C. Does accumulating exposure to illicit drugs bring forward the age at onset in schizophrenia?. Aust. N. Z. J. Psychiatry 2013, 47(1):51-58.
29. Proal A.C., Fleming J., Galvez-Buccollini J.A., Delisi L.E. A controlled family study of cannabis users with and without psychosis. Schizophr. Res. 2014, 152(1):283-288.
30. Rabinowitz J., Bromet E.J., Lavelle J., Carlson G., Kovasznay B., Schwartz J.E. Prevalence and severity of substance use disorders and onset of psychosis in first-admission psychotic patients. Psychol. Med. 1998, 28(6):1411-1419.
31. Ringen P.A., Lagerberg T.V., Birkenaes A.B., Engn J., Faerden A., Jonsdottir H., Nesvag R., Friis S., Opjordsmoen S., Larsen F., Melle I., Andreassen O.A. Differences in prevalence and patterns of substance use in schizophrenia and bipolar disorder. Psychol. Med. 2008, 38(9):1241-1249.
32. Roy M.A., Walsh D., Kendler K.S. Accuracies and inaccuracies of the family history method: a multivariate approach. Acta Psychiatr. Scand. 1996, 93(4):224-234.
33. Sevy S., Robinson D.G., Napolitano B., Patel R.C., Gunduz-Bruce H., Miller R., McCormack J., Lorell B.S., Kane J. Are cannabis use disorders associated with an earlier age at onset of psychosis? A study in first episode schizophrenia. Schizophr. Res. 2010, 120(1-3):101-107.
34. Stefanis N.C., Dragovic M., Power B.D., Jablensky A., Castle D., Morgan V.A. Age at initiation of cannabis use predicts age at onset of psychosis: the 7- to 8-year trend. Schizophr. Bull. 2013, 39(2):251-254.
35. Tosato S., Lasalvia A., Bonetto C., Mazzoncini R., Cristofalo D., De Santi K., Bertani M., Bissoli S., Lazzarotto L., Marrella G., Lamonaca D., Riolo R., Gardellin F., Urbani A., Tansella M., Ruggeri M., Group P.-V. The impact of cannabis use on age of onset and clinical characteristics in first-episode psychotic patients. Data from the Psychosis Incident Cohort Outcome Study (PICOS). J. Psychiatr. Res. 2013, 47(4):438-444.
36. van der Meer F.J., Meijer J.H., Meijer C.J., van den Brink W., Velthorst E. Cognitive functioning associated with stimulant use in patients with non-affective psychosis, their unaffected siblings and healthy controls. Psychol. Med. 2014, 44(9):1901-1911.
37. Weibell M., Joa I., Bramness J., Johannessen J., McGorry P., ten Velden Hegelstad W., Larsen T.K. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry 2013, 13(1):319.